TransCode Therapeutics, Inc. (RNAZ)
RNAZ Stock Price Chart
Explore TransCode Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RNAZ price movements and trends.
RNAZ Company Profile
Discover essential business fundamentals and corporate details for TransCode Therapeutics, Inc. (RNAZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Jul 2021
Employees
7.00
CEO
Thomas A. Fitzgerald
Description
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ Financial Timeline
Browse a chronological timeline of TransCode Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 14 Aug 2025
EPS came in at -$4.94 surpassing the estimated -$8.68 by +43.09%.
Stock split effective on 15 May 2025
Shares were split 1 : 28 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2025
EPS came in at -$16.81 falling short of the estimated -$3.21 by -423.68%.
Earnings released on 28 Mar 2025
EPS came in at -$16.61 surpassing the estimated -$105.93 by +84.32%.
Stock split effective on 4 Dec 2024
Shares were split 1 : 33 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$5.28 surpassing the estimated -$16.17 by +67.35%.
Earnings released on 14 Aug 2024
EPS came in at -$24.42 falling short of the estimated -$19.14 by -27.59%.
Earnings released on 15 May 2024
EPS came in at -$21.45 surpassing the estimated -$23.10 by +7.14%.
Earnings released on 29 Mar 2024
EPS came in at -$99.99 falling short of the estimated -$10.80 by -825.83%, while revenue for the quarter reached $753.15K .
Stock split effective on 16 Jan 2024
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$2.22K falling short of the estimated -$1.98K by -12.00%.
Earnings released on 14 Aug 2023
EPS came in at -$4.34K surpassing the estimated -$4.48K by +2.95%.
Stock split effective on 23 May 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2023
EPS came in at -$10.30K falling short of the estimated -$10.03K by -2.63%.
Earnings released on 30 Mar 2023
EPS came in at -$0.23 surpassing the estimated -$0.38 by +39.47%.
Earnings released on 14 Nov 2022
EPS came in at -$8.71K surpassing the estimated -$10.56K by +17.50%.
Earnings released on 15 Aug 2022
EPS came in at -$9.50K falling short of the estimated -$0.30 by -3.17M%.
Earnings released on 16 May 2022
EPS came in at -$7.13K .
Earnings released on 31 Mar 2022
EPS came in at -$6.07K falling short of the estimated -$200.00 by -2.94K%.
Earnings released on 15 Nov 2021
EPS came in at -$5.28K .
Earnings released on 23 Aug 2021
EPS came in at $589.73 .
Earnings released on 9 Jul 2021
EPS came in at -$278.07 .
Earnings released on 31 Dec 2020
EPS came in at -$100.46 .
Earnings released on 30 Sept 2020
EPS came in at -$172.19 .
RNAZ Stock Performance
Access detailed RNAZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.